Analysts’ Recent Ratings Changes for Moderna (MRNA)

Moderna (NASDAQ: MRNA) recently received a number of ratings updates from brokerages and research firms:

• 1/29/2025 – Moderna was downgraded by analysts at The Goldman Sachs Group, Inc. from a “buy” rating to a “neutral” rating. They now have a $51.00 price target on the stock, down previously from $99.00.
• 1/28/2025 – Moderna had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $112.00 to $99.00. They now have a “buy” rating on the stock.
• 1/27/2025 – Moderna had its price target lowered by analysts at Evercore ISI from $60.00 to $50.00. They now have an “in-line” rating on the stock.
• 1/16/2025 – Moderna had its price target lowered by analysts at Leerink Partners from $31.00 to $27.00. They now have an “underweight” rating on the stock.
• 1/16/2025 – Moderna had its price target raised by analysts at Berenberg Bank from $33.00 to $42.00. They now have a “hold” rating on the stock.
• 1/15/2025 – Moderna had its price target lowered by analysts at Morgan Stanley from $70.00 to $38.00. They now have an “equal weight” rating on the stock.
• 1/8/2025 – Moderna had its price target lowered by analysts at UBS Group AG from $108.00 to $96.00. They now have a “buy” rating on the stock.
• 12/18/2024 – Moderna was downgraded by analysts at Argus from a “buy” rating to a “hold” rating.
• 12/10/2024 – Moderna had its “underperform” rating reaffirmed by analysts at Bank of America Co.. They now have a $41.00 price target on the stock.

Moderna Trading Down 3.2 %

MRNA traded down $1.45 on Wednesday, reaching $43.49. 6,137,620 shares of the company traded hands, compared to its average volume of 12,465,947. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The company has a market cap of $16.74 billion, a P/E ratio of -7.47 and a beta of 1.60. The firm has a fifty day simple moving average of $40.79 and a two-hundred day simple moving average of $62.18. Moderna, Inc. has a one year low of $31.94 and a one year high of $170.47.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same period last year, the business posted ($1.39) EPS. Moderna’s quarterly revenue was up 3.8% on a year-over-year basis. As a group, equities research analysts expect that Moderna, Inc. will post -9.27 earnings per share for the current year.

Insider Transactions at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last quarter, insiders sold 2,664 shares of company stock valued at $115,210. Company insiders own 15.70% of the company’s stock.

Institutional Trading of Moderna

A number of institutional investors have recently modified their holdings of the company. Axiom Advisory LLC increased its position in shares of Moderna by 1.6% in the 3rd quarter. Axiom Advisory LLC now owns 12,672 shares of the company’s stock valued at $847,000 after acquiring an additional 198 shares during the period. Arkadios Wealth Advisors raised its stake in shares of Moderna by 2.2% in the third quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company’s stock worth $764,000 after purchasing an additional 243 shares during the last quarter. Knuff & Co LLC boosted its position in Moderna by 5.4% in the third quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock valued at $316,000 after buying an additional 244 shares during the last quarter. Stephens Inc. AR increased its holdings in Moderna by 7.9% in the 3rd quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock worth $223,000 after buying an additional 245 shares during the period. Finally, Mather Group LLC. raised its position in Moderna by 25.7% during the 3rd quarter. Mather Group LLC. now owns 1,281 shares of the company’s stock worth $86,000 after buying an additional 262 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.